Purposeful studies focused on the development of game-changing therapeutic agents.
Publication: Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.
At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies.